Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Connect Biopharma Holdings ( (CNTB) ) has shared an update.
On March 29, 2026, Connect Biopharma entered into a securities purchase agreement for a $20.2 million private placement of 6,130,000 ordinary shares at $3.25 per share, with closing expected on March 31, 2026, to strengthen its balance sheet under Nasdaq rules. The company said the proceeds, combined with existing cash and investments, should fund operations into the second half of 2027, supporting research and development of rademikibart and other programs, and committed to register the resale of the new shares after closing.
On March 30, 2026, Connect Biopharma reported positive topline preliminary results from a Phase 1 clinical pharmacology study of intravenous rademikibart in patients with asthma and COPD, where a single 300 mg two-minute IV push produced rapid and clinically meaningful FEV1 improvements as early as 15 minutes that were generally maintained through Day 29, with a favorable safety profile. On the same day, the company also announced results from a Phase 3 52-week atopic dermatitis study conducted by China partner Simcere and highlighted ongoing Phase 2 Seabreeze STAT studies in acute exacerbations of asthma and COPD, underscoring both its respiratory pipeline momentum and the strategic importance of its China collaboration.
The most recent analyst rating on (CNTB) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Connect Biopharma Holdings stock, see the CNTB Stock Forecast page.
Spark’s Take on CNTB Stock
According to Spark, TipRanks’ AI Analyst, CNTB is a Neutral.
The score is held back primarily by continued cash burn and lack of profitability despite improving revenue and narrower losses, partially offset by a low-debt balance sheet. Technicals are constructive with the stock trading above major moving averages and positive momentum indicators, while valuation support is limited due to negative earnings and no dividend yield.
To see Spark’s full report on CNTB stock, click here.
More about Connect Biopharma Holdings
Connect Biopharma Holdings is a clinical-stage biopharmaceutical company headquartered in San Diego, focused on developing therapies for inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease. Its lead asset is rademikibart, a next-generation anti-IL-4Rα monoclonal antibody being advanced globally for acute exacerbations in asthma and COPD, with commercialization rights in Greater China licensed to Simcere Pharmaceutical.
Under its agreement with Simcere, Connect Biopharma remains eligible for up to about $110 million in remaining development, regulatory and commercial milestone payments, along with tiered royalties up to the low double digits on net sales in Greater China. This partnership structure underpins the company’s regional strategy while it continues to drive late-stage development of rademikibart in major respiratory indications outside China.
Average Trading Volume: 124,757
Technical Sentiment Signal: Buy
Current Market Cap: $192.9M
For detailed information about CNTB stock, go to TipRanks’ Stock Analysis page.